Business Wire

VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART


Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, presents the target market for its active substance TOTUM-070, for untreated mild to moderate LDL-hypercholesterolemia. The Phase II clinical study has been initiated and will begin as soon as authorizations are received from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP).

TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols nor red yeast rice, developed to act on lipid metabolism in individuals with hypercholesterolemia.

Once development is complete, this new Health Nutrition product will be positioned mainly for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 could be advised to this large population for whom no first-line treatment is currently recommended. It aims at lowering LDL-cholesterol levels and thereby reducing overall cardiovascular risk.

Dr. Josep INFESTA, MD, Head of Business Development at VALBIOTIS2, explains: "Excess LDL-cholesterol is a widespread cardiovascular risk factor, found in nearly 40% of the world's adult population, based on WHO data. In line with our prevention strategy, our active substance TOTUM-070 is a new solution for at-risk individuals, yet untreated according to the current guidelines. Market data supports our analysis: nearly 1.2 billion euros are spent on non-drug products for LDL-cholesterol in the USA and the 5 major European countries. TOTUM-070 is expected to show strong efficacy at the end of its clinical development, which would give it a clear advantage in the untreated hypercholesterolemia market."

The Phase II randomized, double-blind, placebo-controlled clinical study will include 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL. Participants will be divided into two equivalent arms of 60 people, receiving TOTUM-070 or placebo for six months. The primary endpoint of the study will be the reduction of blood LDL-cholesterol levels, with several secondary endpoints of interest. The study has just been initiated, the protocol having been submitted to the ANSM and CPP. The first subject's first visit is scheduled for the first quarter of 2021, and results are expected by the end of 2021 or early 2022.

Following VALBIOTIS’ business model, the objective is to conclude a partnership and licensing agreement for the marketing of TOTUM-070, with a global health player.

Untreated hypercholesterolemia: a major market for non-drug products

In the 5 major European countries (France, Germany, Italy, Spain, United Kingdom) and the United States, an estimated 174 million adults have high LDL-cholesterol1,3. The general public in these countries is very familiar with this health issue, supporting wide screening, and diagnosis rates are high, approaching 50%. The diagnosed population currently stands at 83 million people1.

However, and in accordance with recommendations, only subjects at high overall cardiovascular risk benefit from treatment. A large proportion of those diagnosed therefore already uses non-drug products, particularly in the USA (54% of individuals diagnosed), the UK (58%), France (34%) and Germany (35%)1. The market for such LDL-cholesterol products is currently estimated at nearly €1.2 billion in these regions, including more than €600 million in the United States1.







Persons aged more than 25 years old
with elevated LDL-cholesterol3,







Persons diagnosed with elevated LDL-cholesterol (millions)







% of persons aged more than 25 years old, diagnosed
and already using non drug
products against LDL-cholesterol







LDL-hypercholesterolemia treatment: the need for effective products from the earliest stages

According to current European and American recommendations (ESC, AAC, EAS4), the treatment of LDL-hypercholesterolemia is individually defined, based on LDL-cholesterol levels and overall cardiovascular risk5,6. The SCORE (Systematic Coronary Risk Evaluation) index, for example, classifies patients according to five risk levels, from "low" to "very high", taking into account each individual's cardiovascular risk factors (tobacco, alcohol, overweight, high blood pressure, etc.).

The prescription of first-line lipid-lowering treatment7 is currently indicated for patients with high cardiovascular risk and/or high LDL-cholesterol levels5,6.

The vast majority of people at lower or moderate risk are first advised to make lifestyle changes (diet and physical activity), with the prospect of treatment if blood LDL-cholesterol levels remain uncontrolled.

Professor Jean-Marie BARD, PharmD, PhD, University Professor and Hospital Practitioner at Nantes University Hospital, scientific advisor for the Phase II clinical study, confirms: "We now know how to treat high-risk patients with effective drugs, generally statins, which have a favorable risk/benefit ratio in such cases. Nevertheless, individual variability exists and adverse events have been identified, leading to non-compliance and treatment discontinuation. Moreover, for all other people, with no imminent cardiovascular risk, only lifestyle changes can be proposed, with variable results. For these two populations, we need additional effective and well-tolerated clinical tools that rapidly reduce LDL-cholesterol before the situation deteriorates. TOTUM-070 could very well meet this need."

LDL-cholesterol, a key cardiovascular risk factor

According to international scientific societies, LDL-cholesterol is considered the number one risk factor for atherosclerosis6.

When present in excessive concentrations in the blood, LDL-cholesterol leads to the formation and deposition of atheromatous plaques (essentially the accumulation of fats and blood cells) on artery walls: this is atherosclerosis, a severe cardiovascular disease that causes strokes, myocardial infarction and peripheral artery disease5. Atherosclerosis is associated with very high morbidity and mortality: the rupture of an atheromatous plaque, for example, is the cause of 80% of sudden deaths in adults8.

Globally every year, excess blood LDL-cholesterol is directly responsible for 4.3 million deaths and the loss of 88.7 million years of healthy life9.


VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health world.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).

VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ status awarded by BPI France. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS:

1 AEC Partners Data, 2019
2 External consultant
3 Blood levels of LDL-cholesterol greater than 100 or 130 mg/dL, based on available data
4 European Society of Cardiology, American Association of Cardiology, European Atherosclerosis Society
5 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
6 2018 Guideline on the Management of Blood Cholesterol, a report from the American College of Cardiology / American Heart Association, Journal Of The American College Of Cardiology, 2019
7 Treatment to reduce the level of lipids in the blood (e.g., cholesterol and triglycerides)
9 GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the Global Burden of Disease study 2015. Lancet. 2016.

ISIN Code: FR0013254851
Mnemonic Code: ALVAL
EnterNext© PEA-SME 150


This press release contains forward-looking statements about VALBIOTIS’ objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 120-018). This document is available on the Company’s website (

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.

Contact information

+33 5 46 28 62 58

Stéphane RUIZ
33 1 56 88 11 14

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales to Deliver the World’s First Fully Integrated Unmanned Mine Countermeasures System for the Royal Navy and French “Marine Nationale”26.11.2020 20:55:00 CETPress release

Following the first phase of the program in which two demonstrators have successfully proven their operational performances at sea, France and the United Kingdom marked the tenth anniversary of the Lancaster House treaties by signing a joint contract for Thales to start the production phase of MMCM to deliver eight unmanned mine hunting systems (four for France and four for the United Kingdom). This press release features multimedia. View the full release here: MMCM system at sea ©Thales With the threat of mines and improvised explosive devices present in all conflicts involving naval forces, countries need to strengthen the protection of their maritime domain, to ensure the protection of their assets and to safeguard the freedom of civil navigation. At the same time, it is essential to limit human exposure to mines. With 50 years of expertise serving navies around the world, Thales develops technologies that enable the transiti

Saudi Urban20 Chair Wishes Italy ‘Buona Fortuna’ With the 2021 Urban20 Presidency26.11.2020 14:47:00 CETPress release

TheUrban20 (U20) Chair, His Excellency Fahd Al-Rasheed, President of the Royal Commission for Riyadh City has today wished his Italian counterparts good luck or “Buona Fortuna” as Italy prepares to take up the reins of the 2021 G20 Presidency and the engagement group of cities, the U20. This press release features multimedia. View the full release here: HE Fahd Al-Rasheed, chair of U20 Riyadh 2020 - (Photo - AETOSWire) “The city of Riyadh is immensely proud and honored to have Chaired the 2020 U20. We are proud of the progress we made together as the U20 of 42 cities and 30 think tanks, universities, and multi-lateral entities. We collaborated, innovated and found common ground. We discussed challenges and solutions experienced by cities across every continent. We focused on the common goal of rebuilding better. As we worked to bring urban issues to the fore, a record 39 mayors and representatives of leading cities endorsed the

DEWA Innovation Centre and 800MW 3rd Phase of the Mohammed bin Rashid Al Maktoum Solar Park Inaugurated26.11.2020 14:31:00 CETPress release

HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has inaugurated Dubai Electricity and Water Authority’s (DEWA’s) Innovation Centre and the 800MW third phase of the Mohammed bin Rashid Al Maktoum Solar Park, the largest single-site solar park in the world. The solar park has a planned capacity of 5,000MW by 2030, with investments up to AED50 billion. This press release features multimedia. View the full release here: DEWA Innovation Centre and 800MW 3rd phase of the Mohammed bin Rashid Al Maktoum Solar Park inaugurated (Photo: AETOSWire) HH Sheikh Mohammed bin Rashid Al Maktoum was briefed by HE Saeed Mohammed Al Tayer, MD & CEO of DEWA, about the Innovation Centre, which is a global hub for renewable and clean energy innovation. It supports innovation and creativity in clean and renewable energy, promotes sustainability, develops Emirati talent and enhances the UAE’s com

Leveraging Its Mobile ID, IDEMIA Brings Digital Travel Credentials to Life26.11.2020 14:30:00 CETPress release

Digital Travel Credentials make traveling between airports and airlines a more enjoyable experience and bolsters passenger trust in airport services and systems. On 10-11 November 2020, at the ICAO virtual conference, IDEMIA demonstrated with an airline partner its breakthrough innovation capabilities to present a fully operational solution, bringing DTC to life. This press release features multimedia. View the full release here: (Photo: Buiness Wire) Leveraging its Mobile ID solution and passenger flow facilitation solutions, IDEMIA simulated a passenger DTC for check in and smart boarding. Passengers can speed through all airport touchpoints thanks to fast and ultra-secure biometric identification. IDEMIA’s DTC treat private data with the same security level as for paper passports. “This DTC demonstrator illustrates the innovative capabilities of IDEMIA to perform a highly secure, reliable and smooth identity verification of t

Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda26.11.2020 11:30:00 CETPress release

Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies. Egle has leveraged its unique bioinformatic and translational capabilities to successfully identify targets that will now be pursued under the terms of the alliance. Upon achievement of the target identification, Egle will receive an R&D milestone payment and investment from Takeda. Luc Boblet, CEO of Egle, commented “Reaching this first technical milestone marks our positive progress towards our joint goal with Takeda, of cr

Technology Entrepreneurs Choose Chengdu as Destination and Benefit From the City’s International Business-Friendly Environment26.11.2020 09:23:00 CETPress release

Chengdu has long had an international reputation as a highly livable city. In recent years, Chengdu has also cultivated a business-friendly environment aligned with international standards, making the city fertile soil for enterprise development, especially in the tech sector. XGIMI Technology, a Chengdu-based leading provider of multi-functional smart projectors and laser TVs in China, attributed part of its success to Chengdu’s favorable environment, helping the firm to grow and in 2018 surpass global giants Epson and Sony in the Chinese projector market for the first time. This press release features multimedia. View the full release here: XGIMI Technology Founder Mr. Zhong Bo (Photo: Business Wire) According to data on China’s projector market in the first half of 2020 released by IDC, XGIMI ranked first in terms of shipments and sales, with a market share of 22%. Five XGMI models feature in the top ten projectors by shipmen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom